No Prescription |
 |
 | ||
|
NATAMET Natacyn |
|
| ||
No Prescription » Prescription Drugs 11 » NATAMET Natacyn Natamycin is naturally occuring antimicrobial agent. Antifungal drug used to treat fungal keratitis. It is especially effective against Aspergillus and Fusarium corneal infections. Buy NATAMET Natacyn and other Prescription Drugs 11 products online at Medstore. Buy Online at Medstore - Click Here!
About NATAMET Natacyn: Product Type: Prescription Drugs 11 NATAMET ( Natacyn Generic Natamycin ) NATAMET (Natacyn Generic Natamycin) Natacyn Generic Natamycin 5% Natacyn Generic Natamycin NATAMET
View more Prescription Drugs 11 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
